Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)
Hong Kong
· Delayed Price · Currency is HKD
74.90
-4.10 (-5.19%)
At close: Apr 29, 2026
HKG:2659 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 49.16 | 6.16 | 6.93 |
| Revenue Growth (YoY) | 697.99% | -11.11% | - |
| Cost of Revenue | 5.41 | 1.14 | 0.15 |
| Gross Profit | 43.75 | 5.02 | 6.78 |
| Selling, General & Admin | 108.13 | 115.54 | 47.58 |
| Research & Development | 248.24 | 250.73 | 132.55 |
| Other Operating Expenses | -3.59 | -1.77 | -6.68 |
| Operating Expenses | 352.79 | 364.51 | 173.45 |
| Operating Income | -309.04 | -359.49 | -166.66 |
| Interest Expense | -5.97 | -4.56 | -3.66 |
| Interest & Investment Income | 6.14 | 4.65 | 7.9 |
| Earnings From Equity Investments | -0.24 | -0.61 | -0.92 |
| Currency Exchange Gain (Loss) | -7.47 | 1.19 | 2.97 |
| Other Non Operating Income (Expenses) | -25.19 | -5.57 | - |
| EBT Excluding Unusual Items | -341.77 | -364.38 | -160.37 |
| Gain (Loss) on Sale of Investments | 3.22 | - | - |
| Gain (Loss) on Sale of Assets | 0.01 | -0.08 | -0.03 |
| Legal Settlements | -56.76 | - | - |
| Pretax Income | -395.3 | -364.46 | -160.4 |
| Income Tax Expense | - | -0.02 | -0 |
| Net Income | -395.3 | -364.43 | -160.4 |
| Net Income to Common | -395.3 | -364.43 | -160.4 |
| Shares Outstanding (Basic) | 290 | 268 | 253 |
| Shares Outstanding (Diluted) | 290 | 268 | 253 |
| Shares Change (YoY) | 8.43% | 5.82% | - |
| EPS (Basic) | -1.36 | -1.36 | -0.63 |
| EPS (Diluted) | -1.36 | -1.36 | -0.63 |
| Free Cash Flow | -333.41 | -338.06 | -276.58 |
| Free Cash Flow Per Share | -1.15 | -1.26 | -1.09 |
| Gross Margin | 89.00% | 81.49% | 97.85% |
| Operating Margin | -628.68% | -5835.80% | -2404.96% |
| Profit Margin | -804.18% | -5916.12% | -2314.50% |
| Free Cash Flow Margin | -678.27% | -5487.91% | -3991.02% |
| EBITDA | -273.91 | -329.76 | -146.12 |
| D&A For EBITDA | 35.12 | 29.73 | 20.55 |
| EBIT | -309.04 | -359.49 | -166.66 |
Source: S&P Capital IQ. Standard template.
Financial Sources.